Effect of hormone therapy on BP in normotensive and hypertensive postmenopausal women

Maturitas

Volumn 49, Issue 3, 2004, Pages 189-203

  Mueck, Alfred O ^a   Seeger, Harald ^a  

^a University Women's Hospital   (Germany)

Author keywords

BP; Hormone replacement therapy; Hypertension

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; HORMONIN; PLACEBO;

ARTERIOSCLEROSIS; BIOSIS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIASTOLE; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG MECHANISM; EMBASE; FEMALE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; MEDICAL LITERATURE; MEDLINE; MENOPAUSE; NONHUMAN; POSTMENOPAUSE; REVIEW; RISK FACTOR; SYSTOLE; TIME;

EID: 5644227800     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2004.01.010     Document Type: Article

References (95)

1. Fish I.R., Freedman S.H., Myatt A.V. Oral contraceptives, pregnancy and blood pressure. JAMA. 222:1972;1507-1510
2. Cardoso F., Polonia J., Santos A., Silva-Carvalho J., Ferreira-de-Almeida J. Low-dose oral contraceptives and 24-hour ambulatory blood pressure. Int. J. Gynaecol. Obstet. 59:1997;237-243
3. Nichols M., Robinson G., Bounds W., Newman B., Guillebaud J. Effect of four combined oral contraceptives on blood pressure in the pill-free interval. Contraception. 47:1993;367-376
4. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996;348:505-10.
5. Crane M.G., Harris J.J., Windsor W. Hypertension. Ann. Intern. Med. 74:1971;13-21
6. Women's Health Initiative Writing Group. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
7. Neves-e-Castro M., Samsioe G., Dören M., Skouby S. Results from WHI and HERS II - implications for women and the precriber of HRT. Maturitas. 42:2002;255-258
8. Genazzani A.R., Van der Mooren M.J., Speroff L., Dören M., Pines A. Critical comments. Maturitas. 44:2003;11-18
9. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J.M., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin. Trials. 17:1996;1-12
10. Collins P. Vascular effects of hormones. Maturitas. 38:2001;45-51
11. Lippert T.H., Seeger H., Mueck A.O. Estrogens and the cardiovascular system: role of estradiol metabolites in hormone replacement therapy. Climacteric. 1:1999;296-301
12. Smolders R.G.V., Van der Mooren M.J., Kenemans P., Van der Linden P.W.J., Stehouwer C.D.A., Sipkema P. 17Beta-estradiol induces a rapid, endothelium-dependent, sex-specific vasodilatation in spontaneous constricted rat arterioles. Am. J. Obstet. Gynecol. 187:2002;375-381
13. Mueck A.O., Seeger H., Lippert C., Wallwiener D. Urinary excretion of vasoactive markers following estrogen replacement therapy in postmenopausal women. Int. J. Clin. Pharm. Ther. 38:2000;381-386
14. Mueck A.O., Seeger H., Lippert T.H. Calciumantagonistic effect of natural and synthetic extrogens - investigations on a nongenomic mechanism of direct vascular action. Int. J. Clin. Pharm. Ther. 32:1996;424-427
15. Lippert T.H., Seeger H., Mueck A.O., Hanke H., Haasis R. Effect of estradiol, progesterone, and progestogens on calcium influx in cell cultures af human vessels. Menopause. 3:1996;33-37
16. Kuhl H. Adverse effects of estrogen treatment: natural vs. synthetic estrogens. In: Lippert TH, Mueck AO, Ginsburg J, editors. Sex steroids and the cardiovascular system. New York, London: Parthenon Publishing Group; 1998. p. 201-10.
17. Lippert T.H., Seeger H., Mueck A.O. Clinical and pharmacological characteristics of the conjugated equine estrogens. Is their use in postmenopausal hormone replacement therapy still up to date? Arzneimitteltherapie. 17:1999;362-364
18. Mashchak C.A., Lobo R.A. Estrogen replacement therapy and hypertension. J. Reprod. Med. 30(Suppl. 10):1985;805-810
19. Shionoiri H., Eggena P., Barrett J.D. An increase in high molecular-weight renin substrate associated with estrogenic hypertension. Biochem. Med. 29:1983;14-22
20. Lobo R.A. Estrogens and the risk of coagulopathy. Am. J. Med. 92:1992;283-285
21. Tepper R., Goldberger S., May J.Y., Luz I.J., Beyth Y. Hormonal replacement therapy in postmenopausal women and cardiovascular disease: an overview. Obstet. Gynecol. 47:1992;426-431
22. Birkhäuser M., Braendle W., Breckwoldt M., Keller P.J., Kuhl H., Runnebaum B. 23. Arbeitstreffen des "Zürcher Gesprä chskreises" Dez. 1999. Empfehlungen zur Substitution mit Östrogenen und Gestagenen im Klimakterium und in der Postmenopause. Frauenarzt. 41:2000;599-602
23. Mikkola T.S., Clarkson T.B. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc. Res. 53:2002;605-619
24. Mueck AO, Römer T. Stoffwechsel und hormonsubstitution. New York: Georg Thieme Verlag Stuttgart; 2002. p. 56-74.
25. Seeger H., Mueck A.O., Teichmann A.T., Lippert T.H. Effect of sequential estrogen/progestin treatment on biochemical vasoactive markers in postmenopausal women comparing oral and transdermal application. Clin. Exp. Obstet. Gynecol. 27:2000;17-20
26. Mueck A.O., Seeger H., Haasis R., Gohlke-Bärwolf C., Schieber M., Schuchert A., et al. Effect of oral vs. transdermal estradiol on NO/cGMP during exercise in women with coronary artery disease - randomized, double-blind, placebo-controlled cross over study. Circulation. 100(Suppl. 18):1999;1386
27. Mueck A.O., Seeger H., Korte K., Haasis R., Lippert T.H. Is there any effect of estradiol on the vasodilating NO/cGMP-system? Investigations on the mechanism of cardiovascular protection by estrogen substitution in postmenopausal women. Zentralbl. Gynakol. 116:1994;507-511
28. Mueck A.O., Seeger H., Wiesner J., Korte K., Lippert T.H. Urinary prostanoids in postmenopausal women after transdermal and oral estrogen therapy. J. Obstet. Gynaecol. 14:1994;341-345
29. Kuhl H. Vascular effects of progestogens - biochemistry versus epidemiology. Zentralbl. Gynakol. 121:1999;67-78
30. Casiglia E., d'Este D., Ginocchio G., et al. Menopausal status has no influence on blood pressure and cardiovascular risk. J. Hypertens. 14:1996;729-736
31. Amigoni S., Morelli P., Parazzini F., Chatenoud L. Determinants of elevated blood pressure in women around menopause: results from a cross-sectional study in Italy. Maturitas. 34:1999;25-32
32. Luoto R., Kaprio J., Reunanen A., Rutanenen E.M. Cardiovascular morbidity in relation to ovarian function after hysterectomy. Obstet. Gynecol. 85:1995;515-522
33. Stern M.P., Brown B.W. Jr., Haskall W.L. Cardiovascular risk and use of estrogens or estrogen-progestogen combinations: Stanford three-community study. JAMA. 235:1976;811-815
34. Pallas K.H., Holzwarth G.J., Stern M.P. The effect of conjugated estrogens on the renin-angiotensin system. J. Clin. Endocrinol. Metab. 44:1977;1061-1068
35. Pfeffer R.I. Estrogen use, hypertension and stroke in postmenopausal women. J. Chron. Dis. 31:1978;389-398
36. Barrett-Connor E., Brown V., Turner J. Heart disease risk factors and hormone use in postmenopausal women. JAMA. 241:1979;2167-2168
37. Hazzard W.R. Estrogen replacement and cardiovascular disease: serum lipids and blood pressure effects. Am. J. Obstet. Gyn. 161:1989;1847-1853
38. Hassager C., Christiansen C. Blood pressure during oestrogen/progestogen substitution therapy in healthy post-menopausal women. Maturitas. 9:1988;315-323
39. Pfeffer R.I., v den Noort S. Estrogen use and stroke risk in postmenopausal women. Am. J. Epidemiol. 103:1976;445-456
40. Pfeffer R.I. Estrogen use, hypertension and stroke in postmenopausal women. J. Chron. Dis. 31:1978;389-398
41. Wren B.G., Routledge D.A. Blood pressure changes: oestrogens in climacteric women. Med. J. Aust. 2:1981;528-531
42. Persson I., Adami H.O., Lindberg B.S. Characteristics of estrogen-treated women. II. A descriptive epidemiological study of a Swedish population. Acta Obstet. Gynecol. Scand. 62:1983;297-302
43. Judd H.L., Meldrum D.R., Deftos L.J., Henderson B.E. Estrogen replacement therapy: indications and complications. Ann. Intern. Med. 98:1983;195-205
44. Lindsay R., Herrington B.S. Estrogens and osteoporosis. Semin. Reprod. Endocrinol. 1:1983;55-59
45. Wren B.G., Routledge D.A. The effect of type and dose of oestrogen on the blood pressure of postmenopausal women. Maturitas. 5:1983;135-142
46. Tepper R., Goldberger S., May J.Y., Luz I.J., Beyth Y. Hormonal replacement therapy in postmenopausal women and cardiovascular disease: an overview. Obstet. Gynecol. 47:1992;426-431
47. Persson I., Adami H.O., Lindberg B.S. Characteristics of estrogen-treated women. II. A descriptive epidemiological study of a Swedish population. Acta Obstet. Gynecol. Scand. 62:1983;297-302
48. PEPI Trial, Writing group. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208.
49. Deuringer FU, Mueck AO, Mueck S, Seeger H, Wallwiener D. Progestin effect on blood pressure during combination with transdermal estradiol - chlormadinone acetate vs. norethisterone acetate. In: Aso T, Taketani TYY, Tanaka TSH, Maehara S, editors. Ninth Int Menopause Soc World Congr. Italy: Monduzzi Editore S.p.A. Bologna; 2000. p. 177-81.
50. Mueck A.O., Seeger H., Gräser T., Deuringer F.U., Oettel M., Lippert T.H. Chlormadinone acetate vs. norethisteroneacetate sequentially combined with oral or transdermal estradiol replacement. NS. Arch. Pharmacol. Toxicol. 356:1997;R5-R6
51. Mueck A.O., Gräser T., Seeger H., et al. Is there a dose-dependent effect of dienogest, continuously combined with estradiol valerate, on blood pressure? Exp. Clin. Endocrinol. Diabetes. 106:1998;S36
52. Gräser T., Müller A., Mellinger U., Mueck A.O., Lippert T.H., Oettel M. Continuous combined treatment of the menopause with combinations of oestradiol valerate and dienogest - a dose-ranging study. Maturitas. 35:2000;235-261
53. Mueck A.O., Seeger H., Lüdtke R., Gräser T., Wallwiener D. Effect on biochemical vasoactive markers during postmenopausal HRT: estradiol vs. estradiol/dienogest. Maturitas. 38:2001;305-313
54. Van der Mooren M.J. The influence of postmenopausal oestradiol- dydrogesterone therapy on blood pressure. Maturitas. 27(Suppl):1996;99
55. Kessel H., Kamp O., Kenemans P., et al. Effects of 15 months of 17beta-estradiol and dydrogesterone on systolic cardiac function according to quantitative and Doppler echocardiography in healthy postmenopausal women. Am. J. Obstet. Gynecol. 184:2001;910-916
56. Van Baal W.M., Kenemans P., Stehouwer C.D.A., et al. Sequentially combined hormone replacement therapy reduces impedance to flow within the uterine and central retinal arteries in healthy postmenopausal women. Am. J. Obstet. Gynecol. 181:1999;1365-1373
57. Van Baal W.M., Kenemans P., Emeis J.J., et al. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. Fertil. Steril. 71:1999;663-670
58. Vestergaard P., Hermann A.P., Stilgren L., Tofteng C.L., Sorensen O.H., Eiken P., et al. Effect of 5 years of hormonal replacement therapy on menopausal symptoms and blood pressure - a randomised controlled study. Maturitas. 46:2003;123-132
59. Scuteri A., Bos A.J.G., Brant L.J., Talbot L., Lakatta E.G., Fleg J.L. Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women. Ann. Intern. Med. 135:2001;229-238
60. Foidart JM. Effects of estraderm TTS 50 plus medroxyprogesterone acetate on blood pressure in hypertensive postmenopausal women. In: Cardiovascular disease and HRT. New perspectives. UK: Samsioe G. Parthenon; 1991. p. 41-4.
61. Beljic T., Babic D., Marinkovic J., Prelevic G.M. The effect of hormone replacement therapy on diastolic left ventricular function in hypertensive and normotensive postmenopausal women. Maturitas. 29:1998;229-238
62. Lip G.Y.H., Beevers M., Churchill D., Gareth Beevers D. Hormone replacement therapy and blood pressure in hypertensive women. J Hum. Hypertens. 8:1994;491-494
63. Pines A., Fisman E.Z., Drory Y., et al. The effects of sublingual estradiol on left ventricular function at rest and exercise in postmenopausal women: an echocardiographic assessment. Menopause. 5:1998;79-85
64. Fishman E.Z., Tenenbaum A., Shapira I., Motro M., Pines A. The acute effects of sublingual estradiol on left ventricular diastolic function in normotensive and hypertensive postmenopausal women. Maturitas. 24:1999;145-152
65. Jespersen C.M., Arnung K., Hagen C., et al. Effects of natural oestrogen therapy on blood pressure and renin-angiotensin system in normotensive and hypertensive menopausal women. J. Hypertens. 1:1983;361-364
66. Fenkci S., Fenkci V., Yilmazer M., Serteser M., Koken T. Effects of short-term transdermal hormone replacement therapy on glycaemic control, lipid metabolism, C-reactive protein and proteinuria in postmenopausal women with type 2 diabetes or hypertension. Hum. Reprod. 18:2003;866-870
67. Luotola H. Blood pressure and hemodynamics in postmenopausal women during estradiol-17ß substitution. Ann. Clin. Res. 15(Suppl. 38):1983;1-121
68. Kornhauser C., Malacara J.M., Garay M.E., Perez-Luque E.L. The effect of hormone replacement therapy on blood pressure and cardiovascular risk factors in menopausal women with moderate hypertension. J. Hum. Hypertens. 11:1997;405-411
69. Modena M.G., Muia N., Aveta P., Molinari R., Rossi R. Effects of transdermal estradiol on left ventricular anatomy and performance in hypertensive women. Hypertension. 34:1999;1041-1046
70. Light K.C., Hinderliter A.L., West S.G., et al. Hormone replacement improves hemodynamic profile and left ventricular geometry in hypertensive and normotensive postmenopausal women. J. Hypertens. 19:2001;269-278
71. Mueck A.O. Hypertension and HRT. Int. Congr. Ser. 1229:2002;115-122
72. Akkad A.A., Halligan A.W.F., Abrams K., Al-Azzawi F. Oral vs. transdermal estrogen replacement therapy: effect on 24-h BP. Obstet. Gynecol. 89:1997;97-103
73. Cacciatore B., Paakkari I., Hasselblatt R., et al. Randomized comparison between orally and transdermally administered hormone replacement therapy of long-term effects on 24-hour ambulatory blood pressure in postmenopausal women. Am. J. Obstet. Gynecol. 184:2001;904-909
74. Cagnacci A., Rovati L., Zanni A., Malmusi S., Facchinetti F., Volpe A. Physiological doses of estradiol decrease nocturnal blood pressure in normotensive postmenopausal women. Am. J. Physiol. 276:1999;H1355-H1360
75. Christ M., Seyffart K., Tillmann H.C., Wehling M. Hormone replacement in postmenopausal women: impact of progestogens on autonomic tone and blood pressure regulation. Menopause. 9:2002;127-136
76. Harvey P.J., Wing L.M., Savage J., Molloy D. The effects of different types and doses of oestrogen replacement therapy on clinic and ambulatory blood pressure and the renin-angiotensin system in normotensive postmenopausal women. J. Hypertens. 17:1999;405-411
77. Van Ittersum F.J., Van Baal W.M., Kenemans P., et al. Ambulatory-not office-blood pressures decline during hormone replacement therapy in healthy postmenopausal women. Am. J. Hypertens. 11:1998;1147-1152
78. Seely E.W., Walsh B.W., Gerhard M.D., Williams G.H. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension. 33:1999;1190-1194
79. Vongpatanasin W., Tuncel M., Mansour Y., Arbique D., Victor R.G. Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. Circulation. 103:2001;2903-2908
80. Zacharieva S., Atanassova I., Kirilov G., et al. Effect of transdermal estrogen therapy on some vasoactive humoral factors and 24-h ambulatory blood pressure in normotensive postmenopausal women. Climacteric. 5:2002;293-299
81. Enstrom I., Lidfeldt J., Lindholm L.H., Nerbrand C., Pennert K., Samsioe G. Does blood pressure differ between users and non-users of hormone replacement therapy? The Women's Health in the Lund Area (WHILA) study. Blood Press. 11:2002;240-243
82. Affinito P., Palomba S., Bonifacio M., et al. Effects of hormonal replacement therapy in postmenopausal hypertensive patients. Maturitas. 40:2001;75-83
83. Harvey P.J., Molloy D., Upton J., Wing L.M. Dose response effect of conjugated equine oestrogen on blood pressure in postmenopausal women with hypertension. Blood Press. 9:2000;275-282
84. Manhem K., Ahlm H., Milsom I., Svensson A. Transdermal oestrogen reduces daytime blood pressure in hypertensive women. J. Hum. Hypertens. 12:1998;323-327
85. Mercuro G., Zoncu S., Pilia I., Lao A., Melis G.B., Cherchi A. Effects of acute Estraderm TTS on postmenopausal systemic hypertension. Am. J. Cardiol. 80:1997;652-655
86. Pripp U.M., Hall G., Landgren B.M., Schenck-Gustafsson K. The influence of long-term HRT treatment on ambulatory blood pressure in older women with coronary artery disease. Maturitas. 29(Suppl):1996;89
87. Rosano G.M.C., Leonardo F., Panina G., et al. Impact of chronic transdermal ERT on BP in postmenopausal hypertensive women. J Am Coll Cardiol. 33(2, Suppl A):1999;309A. [Abstract 877-4]
88. Sands R.H., Studd J.W.W., Crook D., Warren J.B., Cruickshank J., Coats A. The effect of estrogen on blood pressure in hypertensive postmenopausal women. Menopause. 4:1997;115-119
89. Zoncu S., Piano D., Pilia I., et al. Estradiol reduces blood pressure and restores the normal amplitude of the circadian blood pressure rhythm in postmenopausal hypertension. Eur. Heart J. 18(Suppl):1997;557
90. Brito-Zurita O.R., Posadas-Romero C., Hermosillo A.G., Zamora-Gonazales J., Hernandez-Ono A., Cardoso-Saldana G., et al. Estrogen effect on heart rate variability in hypertensive postmenopausal women. Maturitas. 44:2003;39-48
91. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 280:1998;605-613
92. Furberg C.D., Vittinghoff E., Davidson M., et al. Subgroup interactions in the Heart and Estrogen/progestin Replacement Study. Lessons learned. Circulation. 105:2002;917-922
93. Grady D., Herrington D., Bittner R., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study Follow-up (HERS II). JAMA. 288:2002;49-57
94. Mueck A.O. Primary and secondary prevention of cardiovascular diseases using hormone replacement therapy in postmenopausal women. Gynäkologe. 36:2003;197-209
95. AHA/ACC Scientific Consensus Panel Statement. Guide to preventive cardiology for women. JACC 1999;33:1751-5.